Literature DB >> 2039356

A pilot study of sphincter-sparing management of adenocarcinoma of the rectum.

G Steele1, P Busse, M S Huberman, J M LeClair, Z M Falchuk, R J Mayer, A Bothe, T S Ravikumar, M Stone, J M Jessup.   

Abstract

After analysis of 26 prospectively accrued patients with distal rectal adenocarcinomas who underwent sphincter preservation treatment, we have concluded that tumors that invade only the submucosa can safely be treated with surgery alone and that tumors that invade the muscularis or further can be safely treated with surgery combined with chemoradiotherapy. None of the patients had either local or distant recurrence, with a median follow-up of 21 months. All patients have been fully continent. The results, although preliminary, imply that resection of distal rectal adenocarcinoma with sphincter preservation, and adjuvant therapy when appropriate, have achieved local and distant control equal to the conventional Miles' abdominoperineal resection, but without the need for a permanent colostomy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2039356     DOI: 10.1001/archsurg.1991.01410300038005

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  7 in total

1.  Long Noncoding RNA GAPLINC Promotes Cells Migration and Invasion in Colorectal Cancer Cell by Regulating miR-34a/c-MET Signal Pathway.

Authors:  Yuqi Luo; Jun Ouyang; Donggen Zhou; Shizhen Zhong; Minjie Wen; Wentao Ou; Haitao Yu; Lin Jia; Yaoxin Huang
Journal:  Dig Dis Sci       Date:  2018-02-09       Impact factor: 3.199

Review 2.  Adjuvant therapy for patients with colorectal cancer.

Authors:  G Steele
Journal:  World J Surg       Date:  1995 Mar-Apr       Impact factor: 3.352

Review 3.  Advances in the treatment of early- to late-stage colorectal cancer: 20 years of progress.

Authors:  G Steele
Journal:  Ann Surg Oncol       Date:  1995-01       Impact factor: 5.344

4.  Total rectal resection, mesorectum excision, and coloendoanal anastomosis: a therapeutic option for the treatment of low rectal cancer.

Authors:  E Leo; F Belli; S Andreola; M T Baldini; G F Gallino; R Giovanazzi; L Mascheroni; R Patuzzo; M Vitellaro; C Lavarino; R Bufalino
Journal:  Ann Surg Oncol       Date:  1996-07       Impact factor: 5.344

Review 5.  Current options for the management of rectal cancer.

Authors:  Bert H O'Neil; Joel E Tepper
Journal:  Curr Treat Options Oncol       Date:  2007-10

6.  Long non-coding RNA TUG1 promotes endometrial cancer development via inhibiting miR-299 and miR-34a-5p.

Authors:  Lifen Liu; Xin Chen; Ying Zhang; Yanrong Hu; Xiaoqing Shen; Weipei Zhu
Journal:  Oncotarget       Date:  2017-05-09

7.  Long Non-Coding RNA ucoo2kmd.1 Regulates CD44-Dependent Cell Growth by Competing for miR-211-3p in Colorectal Cancer.

Authors:  Xiaoli Wu; Xixi He; Shi Li; Xiaoqun Xu; Xiangjian Chen; Hua Zhu
Journal:  PLoS One       Date:  2016-03-14       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.